Half Year 2026 Grifols SA Earnings Call Transcript
Key Points
- Grifols SA (GRFS) reported a 2.6% revenue growth at constant currency for the first half of 2026, driven primarily by a 5.4% growth in the Biopharma segment.
- The company achieved a significant improvement in free cash flow, increasing by approximately EUR100 million during the first half of the year.
- Grifols SA (GRFS) launched Evanzys immunohematology, marking a significant step for its Diagnostic business and showcasing its commitment to innovation.
- The company is progressing with its plasma strategy, with developments in Egypt and Canada enhancing its plasma sourcing network.
- Grifols SA (GRFS) is considering a potential IPO of its U.S. Biopharma business, which could unlock additional value for the company.
- The company faced temporary headwinds in albumin, particularly in China, due to pricing adjustments made in mid-2025.
- Grifols SA (GRFS) reported a gross margin impact due to one-off costs related to the closure of 29 U.S. donation centers.
- The Diagnostics segment faced challenges due to the dissolution of the Quidel Ortho joint business, impacting year-on-year comparisons.
- There are execution risks associated with the ramp-up of plasma centers in Egypt, although the company remains confident in its strategy.
- The company is managing a strategic transition in its Diagnostics business, which may take time to yield significant results.
Hello, everyone, and thank you for joining us today for Grifols' Second Quarter 2026 Earnings Call. My name is Daniel Segarra, and I serve as the Head of Investor Relations and Sustainability. Today, I'm joined by Grifols' Chief Executive Officer, Nacho Abia; President of Biopharma, Roland Wandeler; and Chief Financial Officer, Rahul Srinivasan.
As this is our usual practice, today's call will last about an hour, including the Q&A session. Please note that this call is being recorded. You can find additional materials, including today's presentation in the Investor Relations section of the Grifols website at grifols.com. A transcript and replay of the webcast will also be available on the Investor Relations website within 24 hours.
Turning to Slide 2. I would like to remind everyone that forward-looking statements may be made during this call. This may include, among other things, comments regarding the company's future operating and financial performance, statements about our future expectations, clinical
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
